MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13176-13200

  Fisher, James Neil ^a   Terao, Mineko ^a   Fratelli, Maddalena ^a   Kurosaki, Mami ^a   Paroni, Gabriela ^a   Zanetti, Adriana ^a   Gianni, Maurizio ^a   Bolis, Marco ^a   Lupi, Monica ^a   Tsykin, Anna ^b,c   Goodall, Gregory J ^b,c   Garattini, Enrico ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Centre for Cancer Biology and Department of Haematology   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Breast cancer; Lapatinib; MicroRNA; Network analysis; Retinoic acid

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 2; LAPATINIB; MICRORNA; MICRORNA 1225 5P; MICRORNA 125A; MICRORNA 193; MICRORNA 210; MICRORNA 29A 3P; MICRORNA 575; MICRORNA 874 3P; PHOSPHATIDYLINOSITOL SPECIFIC PHOSPHOLIPASE C X DOMAIN CONTAINING 1 PROTEIN; PHOSPHOLIPASE C; RETINOIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HIPK2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; RARA PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; OVERALL SURVIVAL; PROTEIN TARGETING; UPREGULATION; BREAST TUMOR; CELL GROWTH; CELL MOTION; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARRIER PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICRORNAS; PHOSPHOINOSITIDE PHOSPHOLIPASE C; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRETINOIN;

EID: 84931036287     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3759     Document Type: Article

References (87)

1. Paroni G, Fratelli M, GardiniG, Bassano C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao M, Garattini E. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB and RARA. Oncogene, 2012; 31:3431-43.
2. Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, Gianni M, Zanetti A, Pagani A, Fisher JN, Zambelli A, Pagani A, Fisher JN, Zambelli A, Terao M. Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev, 2014; 40:739-49.
3. Lujambio A, Lowe SW. The microcosmos of cancer Nature. 2012; 482:347-55.
4. Serpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat Rev, 2014; 40:595-604.
5. Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev, 2009; 35:328-34.
6. Garofalo M, Leva GD, Croce CM. MicroRNAs as anti-cancer therapy. Curr Pharm Des, 2014; 20:5328-35.
7. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol, 2014; 9:287-314.
8. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med, 2012; 4:143-59.
9. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 2009; 10:704-14.
10. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell, 2005; 122:6-7.
11. Das E, Bhattacharyya NP. MicroRNA-432 contributes to dopamine cocktail and retinoic acid induced differentiation of human neuroblastoma cells by targeting NESTIN and RCOR1 genes. FEBS Lett, 2014; 588:1706-14.
12. Das S, Bryan K, Buckley PG, Piskareva O, Bray IM, Foley N, Ryan J, Lynch J, Creevey L, Fay J, Prenter S, Koster J, van Sluis P, et al. Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene, 2013; 32:2927-36.
13. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell, 2005; 123:819-31.
14. Franzosa JA, Bugel SM, Tal TL, La Du JK, Tilton SC, Waters KM, Tanguay RL. Retinoic acid-dependent regulation of miR-19 expression elicits vertebrate axis defects. FASEB J, 2013; 27:4866-76.
15. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, Calin GA, Liu CG, Andreeff M, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene, 2007; 26:4148-57.
16. Kasimanickam VR, Kasimanickam RK, Dernell WS. Dysregulated microRNA Clusters in Response to Retinoic Acid and CYP26B1 Inhibitor Induced Testicular Function in Dogs. PLoS One, 2014; 9:e99433.
17. Sanchez-Martinez D, Krzywinska E, Rathore MG, Saumet A, Cornillon A, Lopez-Royuela N, Martinez-Lostao L, Ramirez-Labrada A, Lu ZY, Rossi JF, Fernandez-Orth D, Escorza S, Anel A, et al. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. Int J Biochem Cell Biol, 2014; 49:p. 42-52.
18. Shi S, LuY, Qin Y, Li W, Cheng H, Xu Y, Xu J, Long J, Liu L, Liu C, Yu X. miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Curr Mol Med, 2014; 14:316-27.
19. Takahashi H, Kanno T, Nakayamada S, Hirahara K, Sciume G, Muljo SA, Kuchen S, Casellas R, Wei L, Kanno Y, O'Shea JJ. TGF-beta and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat Immunol, 2012; 13:587-95.
20. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol, 2008; 10:593-601.
21. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle, 2008; 7:3112-8.
22. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol, 2010; 12:209-11.
23. Khew-Goodall Y, Goodall GJ. Stromal miR-320 keeps an oncogenic secretome in check. Nat Cell Biol, 2012; 14:124-5.
24. Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ, Gregory PA, Khew-Goodall Y. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesindependent pathways. Oncogene, 2014; 33:4077-88.
25. Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, Tekmal RR, Vadlamudi RK. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene, 2014; 33:3707-16.
26. Saumet A, Vetter G, Bouttier M, Antoine E, Roubert C, Orsetti B, Theillet C, Lecellier CH. Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells. Mol Biosyst, 2012; 8:3242-53.
27. Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia V, Paroni G, Tsykin A, Lupi M, Gianni M, Goodall GJ, Garattini E. Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J Biol Chem, 2011; 286:4027-42.
28. Balansky R, Izzotti A, D'Agostini F, Longobardi M, Micale RT, La Maestra S, Camoirano A, Ganchev G, Iltcheva M, Steele VE, De Flora S. Assay of lapatinib in murine models of cigarette smoke carcinogenesis. Carcinogenesis, 2014.
29. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology, 2014; 146:914-28.
30. Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lubbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat, 2014; 147:61-8.
31. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res, 2012; 72:3499-511.
32. Roca-Alonso L, Pellegrino L, Castellano L, Stebbing J. Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology, 2012; 122:253-9.
33. Tu CY, Chen CH, Hsia TC, Hsu MH, Wei YL, Yu MC, Chen WS, Hsu KW, Yeh MH, Liu LC, Chen YJ, Huang WC. Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells. Biomed Res Int, 2014; 2014: p.168949.
34. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol, 2014; 15:178-96.
35. Mallini P, Lennard T, Kirby J, Meeson A. Epithelial-tomesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev, 2014; 40:341-8.
36. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science, 2013; 342:1234850.
37. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol, 2014; 16:488-94.
38. Cieply B, Farris J, Denvir J, Ford HL, Frisch SM. Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res, 2013; 73:6299-309.
39. Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer, 2013; 13:174.
40. Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci U S A, 2012; 109:16654-9.
41. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell, 2011; 145:926-40.
42. Rostas JW, 3rd, Pruitt HC, Metge BJ, Mitra A, Bailey SK, Bae S, Singh KP, Devine DJ, Dyess DL, Richards WO, Tucker JA, Shevde LA, Samant RS. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol Cancer, 2014; 13:200.
43. Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol, 2009; 6:575-83.
44. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S, Fusco A. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest, 2007; 117:693-702.
45. Wesierska-Gadek J, Schmitz ML, Ranftler C. Roscovitineactivated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem, 2007; 100:865-74.
46. Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, Garufi A, Rechavi G, Givol D, D'Orazi G. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol Ther, 2012; 13:198-205.
47. Mithani SK, Smith IM, Califano JA. Use of integrative epigenetic and cytogenetic analyses to identify novel tumorsuppressor genes in malignant melanoma. Melanoma Res, 2011; 21:298-307.
48. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One, 2013; 8:e65138.
49. Tahiri A, Leivonen SK, Luders T, Steinfeld I, Ragle Aure M, Geisler J, Makela R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Borresen-Dale AL, Perala M, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis, 2014; 35:76-85.
50. Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale AL, Perala M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth, Mol Oncol, 2014; 8:93-104.
51. Kastrati I, Canestrari E, Frasor J. PHLDA1 expression is controlled by an estrogen receptor-NFkappaBmiR-181 regulatory loop and is essential for formation of ER+ mammospheres. Oncogene, 2014.
52. Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, Liu X, Su F, Lin L, Yao Y. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One, 2013; 8:e80707.
53. Yu T, Wang XY, Gong RG, Li A, Yang S, Cao YT, Wen YM, Wang CM, Yi XZ. The expression profile of microRNAs in a model of 7, 12-dimethyl-benz[a]anthranceinduced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res, 2009; 28:64.
54. Wu Z, Huang X, Zou Q, Guo Y. The inhibitory role of Mir-29 in growth of breast cancer cells. J Exp Clin Cancer Res, 2013; :32:98.
55. Kesanakurti D, Maddirela DR, Chittivelu S, Rao JS, Chetty C. Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer. Biochem Biophys Res Commun, 2013; 434:627-33.
56. Nohata N, Hanazawa T, Kikkawa N, Sakurai D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nakagawa M, Katayama A, Harabuchi Y, Okamoto Y, et al. Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br J Cancer, 2011; 105:833-41.
57. Nohata N, Hanazawa T, Kinoshita T, Inamine A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto Y, Seki N. Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. Br J Cancer, 2013; 108:1648-58.
58. Gerson KD, Shearstone JR, Maddula VS, Seligmann BE, Mercurio AM. Integrin beta4 regulates SPARC protein to promote invasion. J Biol Chem, 2012; 287:9835-44.
59. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem, 2009; 284:23204-16.
60. Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X, Song L. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One, 2010; 5:e15797.
61. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA, Martens JW. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A, 2008; 105:13021-6.
62. Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene, 2012; 507:135-8.
63. Wang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, Zou Z. Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One, 2014; 9:e89223.
64. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One, 2011; 6:e20980.
65. Luo D, Wilson JM, Harvel N, Liu J, Pei L, Huang S, Hawthorn L, Shi H. A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med, 2013; 11:57.
66. Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res, 2012; 31:58.
67. Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A, 2012; 109:14470-5.
68. Chan SH, Huang WC, Chang JW, Chang KJ, Kuo WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, Jang TH, Tu CW, Lee YR, et al. MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene, 2014; 33:4496-507.
69. Perez-Rivas LG, Jerez JM, Carmona R, de Luque V, Vicioso L, Claros MG, Viguera E, Pajares B, Sanchez A, Ribelles N, Alba E, Lozano J. A microRNA signature associated with early recurrence in breast cancer. PLoS One, 2014; 9:e91884.
70. Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer, 2010; 10:502.
71. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol, 2011; 193:409-24.
72. Kong LM, Liao CG, Zhang Y, Xu J, Li Y, Huang W, Bian H, Chen ZN. A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis. Cancer Res, 2014; 74:3764-78.
73. Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene, 2014; 0.
74. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C. MicroRNA profiling of human gastric cancer. Mol Med Rep, 2009:2:963-70.
75. Pizzimenti S, Ferracin M, Sabbioni S, Toaldo C, Pettazzoni P, Dianzani MU, Negrini M, Barrera G. MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radic Biol Med, 2009; 46:282-8.
76. Hong S, Noh H, Teng Y, Shao J, Rehmani H, Ding HF, Dong Z, Su SB, Shi H, Kim J, Huang S. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia, 2014; 16:279-90. e1-5.
77. Zheng H, Kang Y. Multilayer control of the EMT master regulators. Oncogene, 2014; 33:1755-63.
78. Centritto F, PG, Bolis M, Garattini SK, Kurosaki M, Barzago MM, Zanetti A, Fisher JN, Scott MF, Pattini L, Lupi M, Ubezio P, Piccotti F, Zambelli A, Rizzo P, Gianni' M, Fratelli M, Terao M, Garattini E. Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer:luminal phenotype and RARα expression. EMBO Molecular Medicine, 2015; in press.
79. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell, 2003; 115:177-86.
80. Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol, 2013; 6:6.
81. Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, He X, Yao M. MicroRNA-193a-3p and-5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogen. 2015; 34:413-23.
82. Plumb JA. Cell sensitivity assays: the MTT assay. Methods Mol Med, 2004; 88:165-9.
83. Lupi M, Matera G, Branduardi D, D'Incalci M, Ubezio P. Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach. Cancer Res, 2004; 64:2825-32.
84. Sales G, Coppe A, Bisognin A, Biasiolo M, Bortoluzzi S, Romualdi C. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Nucleic Acids Res, 2010; 38:W352-9.
85. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD, Ideker T. A travel guide to Cytoscape plugins. Nat Methods, 2012; 9:1069-76.
86. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res, 2010; 16:5222-32.
87. Harrington, D.P.A.F. T. R. A class of rank test procedures for censored survival data Biometrika. 1982; 69:553-566.